[1]. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, Jing ZC and Gibbs JS. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4: 306-322.
[2]. Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S and Bonnet S. The cancer theory of pulmonary arterial hypertension. Pulmonary Circulation 2017; 2: 285-299.
[3]. de Jesus PV. Molecular pathogenesis and current pathology of pulmonary hypertension. HEART FAILURE REVIEWS 2016; 3: 239-257.
[4]. Paulin R and Michelakis ED. The metabolic theory of pulmonary arterial hypertension. CIRCULATION RESEARCH 2014; 1: 148-164.
[5]. Tang W, Backhed F, Landmesser U and Hazen SL. Intestinal Microbiota in Cardiovascular Health and Disease: JACC State-of-the-Art Review. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2019; 16: 2089-2105.
[6]. Cummings JH, Pomare EW, Branch WJ, Naylor CP and Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. GUT 1987; 10: 1221-1227.
[7]. Vital M, Howe AC and Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. mBio 2014; 2: e889.
[8]. Duncan SH, Barcenilla A, Stewart CS, Pryde SE and Flint HJ. Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. Appl Environ Microbiol 2002; 10: 5186-5190.
[9]. Louis P, Hold GL and Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. NATURE REVIEWS MICROBIOLOGY 2014; 10: 661-672.
[10]. Callejo M, Mondejar-Parreno G, Barreira B, Izquierdo-Garcia JL, Morales-Cano D, Esquivel-Ruiz S, Moreno L, Cogolludo A, Duarte J and Perez-Vizcaino F. Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome. Sci Rep 2018; 1: 9681.
[11]. Flint HJ, Scott KP, Louis P and Duncan SH. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol 2012; 10: 577-589.
[12]. Koh A, De Vadder F, Kovatcheva-Datchary P and Backhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. CELL 2016; 6: 1332-1345.
[13]. Cantoni S, Galletti M, Zambelli F, Valente S, Ponti F, Tassinari R, Pasquinelli G, Galie N and Ventura C. Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. FEBS Journal 2013; 9: 2042-2055.
[14]. Zhang LT, Yao YM, Lu JQ, Yan XJ, Yu Y and Sheng ZY. Sodium butyrate prevents lethality of severe sepsis in rats. SHOCK 2007; 6: 672-677.
[15]. Shimoda LA, Sylvester JT and Sham JS. Mobilization of intracellular Ca(2+) by endothelin-1 in rat intrapulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000; 1: L157-L164.
[16]. Lionetti V, Cantoni S, Cavallini C, Bianchi F, Valente S, Frascari I, Olivi E, Aquaro GD, Bonavita F, Scarlata I, Maioli M, Vaccari V, Tassinari R, Bartoli A, Recchia FA, Pasquinelli G and Ventura C. Hyaluronan mixed esters of butyric and retinoic acid affording myocardial survival and repair without stem cell transplantation. JOURNAL OF BIOLOGICAL CHEMISTRY 2010; 13: 9949-9961.
[17]. Cai J, Zhang L, Jones RA, Correll JB, Hatzakis E, Smith PB, Gonzalez FJ and Patterson AD. Antioxidant Drug Tempol Promotes Functional Metabolic Changes in the Gut Microbiota. JOURNAL OF PROTEOME RESEARCH 2016; 2: 563-571.
[18]. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR and Wilkins MR. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. CIRCULATION 2012; 4: 455-467.
[19]. Stratton MS and McKinsey TA. Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy. Biochemistry and Cell Biology 2015; 2: 149-157.
[20]. Lu J, McKinsey TA, Zhang CL and Olson EN. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. MOLECULAR CELL 2000; 2: 233-244.
[21]. McKinsey TA, Zhang CL, Lu J and Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. NATURE 2000; 6808: 106-111.
[22]. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT and Semenza GL. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. JOURNAL OF CLINICAL INVESTIGATION 1999; 5: 691-696.
[23]. Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D and Carmeliet P. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. JOURNAL OF CLINICAL INVESTIGATION 2003; 10: 1519-1527.
[24]. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM and Voelkel NF. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. JOURNAL OF PATHOLOGY 2001; 3: 367-374.
[25]. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS, Weir EK and Archer SL. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. CIRCULATION 2006; 22: 2630-2641.
[26]. Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, Voelkel NF and Ishizaki T. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol 2011; 5: L753-L761.
[27]. Malczyk M, Veith C, Fuchs B, Hofmann K, Storch U, Schermuly RT, Witzenrath M, Ahlbrecht K, Fecher-Trost C, Flockerzi V, Ghofrani HA, Grimminger F, Seeger W, Gudermann T, Dietrich A and Weissmann N. Classical transient receptor potential channel 1 in hypoxia-induced pulmonary hypertension. Am J Respir Crit Care Med 2013; 12: 1451-1459.
[28]. Veith C, Zakrzewicz D, Dahal BK, Balint Z, Murmann K, Wygrecka M, Seeger W, Schermuly RT, Weissmann N and Kwapiszewska G. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1alpha depletion or imatinib treatment. Thromb Haemost 2014; 6: 1288-1303.
[29]. Shimoda LA. 55th Bowditch Lecture: Effects of chronic hypoxia on the pulmonary circulation: role of HIF-1. J Appl Physiol (1985) 2012; 9: 1343-1352.
[30]. Abud EM, Maylor J, Undem C, Punjabi A, Zaiman AL, Myers AC, Sylvester JT, Semenza GL and Shimoda LA. Digoxin inhibits development of hypoxic pulmonary hypertension in mice. Proc Natl Acad Sci U S A 2012; 4: 1239-1244.
[31]. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX and Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2009; 1 Suppl: S10-S19.
[32]. Rabinovitch M, Guignabert C, Humbert M and Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. CIRCULATION RESEARCH 2014; 1: 165-175.
[33]. Shalapour S and Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. JOURNAL OF CLINICAL INVESTIGATION 2015; 9: 3347-3355.
[34]. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G and Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 5: 1628-1631.
[35]. Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H and Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. EUROPEAN RESPIRATORY JOURNAL 2009; 3: 662-668.
[36]. He YH, Wang XQ, Zhang J, Liu ZH, Pan WQ, Shen Y, Zhu ZB, Wang LJ, Yan XX, Yang K, Zhang RY, Shen WF, Ding FH and Lu L. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs. Arterioscler Thromb Vasc Biol 2017; 4: 717-729.